The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Deconstructing the Drug Development Process: The New Face of Innovation
Open accessAbstract
Forged in the early 1960s, the paradigm for pharmaceutical innovation has remained virtually unchanged for nearly 50 years. During a period when most other research-based industries have made frequent and often sweeping modifications to their R&D processes, the pharmaceutical sector continues to utilize a drug development process that is slow, inefficient, risky, and expensive. Few who work in or follow the activities of the pharmaceutical industry question whether change is coming. They know that the pharmaceutical sector, as currently structured, is unable to deliver enough new products to market to generate revenues sufficient to sustain its own growth. Nearly all major drug developers are critically examining current R&D practices and, in some cases, considering a radical overhaul of their R&D models. But key questions remain. What will the landscape for pharmaceutical innovation look like in the future? And, who will develop tomorrow's medicines? Clinical Pharmacology & Therapeutics (2010) 87 3, 356–361. doi:10.1038/clpt.2009.293
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.295 · Cited by 845
The cost of biopharmaceutical R&D: is biotech different?
DiMasi, J. A., & Grabowski, H. G. (2007) · Managerial and Decision Economics · doi:10.1002/mde.1360 · Cited by 517
Risks in new drug development: Approval success rates for investigational drugs
DiMasi, J. A. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.115446 · Cited by 450
Returns on Research and Development for 1990s New Drug Introductions
Grabowski, H., Vernon, J., & DiMasi, J. A. (2002) · PharmacoEconomics · doi:10.2165/00019053-200220003-00002 · Cited by 311
Assessing the Impact of Protocol Design Changes on Clinical Trial Performance
Getz, K. A., Wenger, J., Campo, R. A., Seguine, E. S., & Kaitin, K. I. (2008) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31816b9027 · Cited by 147
Self-citationTranslational Medicine: An Engine of Change for Bringing New Technology to Community Health
Milne, C., & Kaitin, K. I. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000222 · Cited by 28
Self-citation
Cited by
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay
Molina, D. M., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., & Nordlund, P. (2013) · Science · doi:10.1126/science.1233606 · Cited by 2,261
Brown, D. G., & Boström, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01409 · Cited by 1,964
The dynamic sustainability framework: addressing the paradox of sustainment amid ongoing change
Chambers, D. A., Glasgow, R. E., & Stange, K. C. (2013) · Implementation Science · doi:10.1186/1748-5908-8-117 · Cited by 1,724
Trends in the exploitation of novel drug targets
Rask-Andersen, M., Almén, M. S., & Schiöth, H. B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3478 · Cited by 853
Delivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718
Gerwick, W. H., & Moore, B. S. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.014 · Cited by 601
Organ-on-a-Chip: A New Paradigm for Drug Development
Ma, C., Peng, Y., Li, H., & Chen, W. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.11.009 · Cited by 576
Faulkner-Jones, A., Fyfe, C., Cornelissen, D.-J., Gardner, J., King, J., Courtney, A., & Shu, W. (2015) · Biofabrication · doi:10.1088/1758-5090/7/4/044102 · Cited by 474
Allied Health Department, P. H. P., Asokan, G., Ramadhan, T., Nursing, C. O. H. S., Ahmed, E., Nursing, C. O. H. S., Sanad, H., & Nursing, C. O. H. S. (2019) · Oman Medical Journal · doi:10.5001/omj.2019.37 · Cited by 382
Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009
Kaitin, K. I., & DiMasi, J. A. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.286 · Cited by 328
Self-citationIn silico methods for drug repurposing and pharmacology
Hodos, R. A., Kidd, B. A., Shameer, K., Readhead, B. P., & Dudley, J. T. (2016) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1337 · Cited by 326
Drug delivery vehicles on a nano-engineering perspective
Felice, B., Prabhakaran, M. P., Rodríguez, A. P., & Ramakrishna, S. (2014) · Materials Science and Engineering: C · doi:10.1016/j.msec.2014.04.049 · Cited by 253
Drug repositioning: Progress and challenges in drug discovery for various diseases
Hua, Y., Dai, X., Xu, Y., Xing, G., Liu, H., Lu, T., Chen, Y., & Zhang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114239 · Cited by 232
An overview of FDA-approved new molecular entities: 1827–2013
Kinch, M. S., Haynesworth, A., Kinch, S. L., & Hoyer, D. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.03.018 · Cited by 210
Cardiovascular Drug Development
Fordyce, C. B., Roe, M. T., Ahmad, T., Libby, P., Borer, J. S., Hiatt, W. R., Bristow, M. R., Packer, M., Wasserman, S. M., Braunstein, N., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.03.016 · Cited by 202
Microengineered Liver Tissues for Drug Testing
Khetani, S. R., Berger, D. R., Ballinger, K. R., Davidson, M. D., Lin, C., & Ware, B. R. (2015) · SLAS Technology · doi:10.1177/2211068214566939 · Cited by 116
“Many arguments have been made that pharmaceutical companies will save millions, if not billions, of dollars by using in vitro models to eliminate toxic compounds from the pipeline and/or to design better drugs prior to reaching human clinical trials or the marketplace where failures can be very costly.(1,2) However, i…”
BackgroundApproaching the in vitro clinical trial: engineering organs on chips
Capulli, A. K., Tian, K., Mehandru, N., Bukhta, A., Choudhury, S. F., Suchyta, M., & Parker, K. K. (2014) · Lab on a Chip · doi:10.1039/c4lc00276h · Cited by 111
Engineered Liver Platforms for Different Phases of Drug Development
Ware, B. R., & Khetani, S. R. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.08.001 · Cited by 90
“, inhibition) against a protein implicated in a disease [1].”
BackgroundShoda, L. K. M., Woodhead, J. L., Siler, S. Q., Watkins, P. B., & Howell, B. A. (2014) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1878 · Cited by 75
Advances in Engineered Liver Models for Investigating Drug-Induced Liver Injury
Lin, C., & Khetani, S. R. (2016) · BioMed Research International · doi:10.1155/2016/1829148 · Cited by 66
Beierlein, J. M., McNamee, L. M., Walsh, M. J., Kaitin, K. I., DiMasi, J. A., & Ledley, F. D. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.06.001 · Cited by 24
Self-citationAdvances in microfluidic 3D cell culture for preclinical drug development
(2022) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2021.07.022 · Cited by 23
Lu, X., Lin, B., Xu, N., Huang, H., Wang, Y., & Lin, J.-M. (2020) · Talanta · doi:10.1016/j.talanta.2020.120732 · Cited by 23
The molecular basis of the anticancer effect of statins
Buccioli, G., Testa, C., Jacchetti, E., Pinoli, P., Carelli, S., Ceri, S., & Raimondi, M. T. (2024) · Scientific Reports · doi:10.1038/s41598-024-71240-6 · Cited by 13
Metadata
- Authors
- Kaitin, K. I.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2010-02-03
- Volume
- 87
- Issue
- 3
- Pages
- 356-361
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W1986672838
- Cited by
- 418
- References
- 6
- FWCI
- 67.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.